Publications

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

Management ownership and market valuation

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor...

Pembrolizumab versus Ipilimumab in Advanced Melanoma

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94

This article introduces MMFF94, the initial published version of the Merck molecular force field (MMFF). It describes the objectives set for MMFF, the form it takes, and the ran...

Update on prevention, diagnosis, and treatment of chronic hepatitis B

Potential conflict of interest: Dr. Hwang received grants from Merck and Gilead. Dr. Chang advises Arbutus. Dr. Lok received grants from Gilead and Bristol‐Myers Squibb. Dr. Jon...

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells

Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions

This article defines the parameterization and performance of MMFF94 for intermolecular interactions. It specifies the novel “buffered” functional forms used for treating van der...

Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94

This article describes the parameterization and performance of MMFF94 for molecular geometries and deformations. It defines the form used for the valence-coordinate terms that r...

Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules

This article describes the extension of the Merck Molecular Force Field (MMFF94) to a much broader range of organic systems. It also describes a preliminary parameterization of ...